Development and validation of a clinical risk model for postoperative outcome in newly diagnosed glioblastoma: A report of the RANO resect group (2025) Karschnia P, Young JS, Youssef GC, Dono A, Häni L, Sciortino T, Bruno F, et al. Journal article Multidisciplinary management strategies for recurrent brain metastasis after prior radiotherapy: An overview (2025) Kotecha R, La Rosa A, Brown PD, Vogelbaum MA, Navarria P, Bodensohn R, Niyazi M, et al. Journal article The inconsistent terminology for the extent of resection in glioblastoma: A systematic review on 6 decades of neuro-oncological studies (2025) Teske NC, Jung LB, Teske N, Thon N, Tonn JC, Karschnia P Journal article Immune signatures of checkpoint inhibitor-induced autoimmunity-A focus on neurotoxicity. (2024) Müller-Jensen L, Schulz AR, Mei HE, Mohr R, Ulrich C, Knape P, Frost N, et al. Journal article Sialic acid metabolism orchestrates transcellular connectivity and signaling in glioblastoma (2023) Kuliesiute U, Joseph K, Straehle J, Ravi VM, Kueckelhaus J, Benotmane JK, Zhang J, et al. Journal article Prognostic evaluation of re-resection for recurrent glioblastoma using the novel RANO classification for extent of resection: A report of the RANO resect group (2023) Karschnia P, Dono A, Young JS, Juenger ST, Teske N, Häni L, Sciortino T, et al. Journal article Targeted anticonvulsive treatment of IDH-wildtype glioblastoma based on DNA methylation subclasses (2023) Drexler R, Göttsche J, Sauvigny T, Schüller U, Khatri R, Hausmann F, Hänzelmann S, et al. Journal article Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group (2023) Karschnia P, Young JS, Dono A, Häni L, Sciortino T, Bruno F, Juenger ST, et al. Journal article Quantitative proteomic landscapes of primary and recurrent glioblastoma reveal a protumorigeneic role for FBXO2-dependent glioma-microenvironment interactions (2023) Buehler M, Yi X, Ge W, Blattmann P, Rushing E, Reifenberger G, Felsberg J, et al. Journal article DNA methylation subclass receptor tyrosine kinase II (RTK II) is predictive for seizure development in glioblastoma patients (2022) Ricklefs FL, Drexler R, Wollmann K, Eckhardt A, Heiland DH, Sauvigny T, Maire C, et al. Journal article